Work

Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.2682.2682

Authors: Shaji Kumar, Joseph R. Mikhael, Betsy R. LaPlant, Joseph P. Colgan, David James Inwards, Patrick B. Johnston, Kristina Laumann, Ivana N. Micallef, Grzegorz S. Nowakowski, Stephen M. Ansell, Kelly Curtis, Angela Dispenzieri, Martha Q Lacy, Jose F. Leis, Donald Northfelt, Craig B. Reeder, James L. Slack, Thomas E. Witzig

Institutions: Mayo Clinic, Mayo Clinic in Arizona

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2557374613

FWCI: 0.353

Cites:

Cited by: 4

Related to: 10